Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
October 19 2020 - 4:42PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, and Sepsis Alliance, the
first and leading sepsis nonprofit in the U.S., announced today
that T2 Biosystems’ President and CEO, John Sperzel, will serve as
a member of the Advisory Board for Sepsis Alliance, effective
immediately. Sepsis Alliance works in all 50 states to save lives
and reduce suffering from sepsis by improving sepsis awareness and
care.
Sperzel will serve on the Industry Council of the Advisory
Board. The Industry Council was created to harness the collective
expertise, resources and relationships of health industry leaders
to improve sepsis awareness and care. Council members advise on
Sepsis Alliance’s industry partnership strategy to maximize reach,
engagement and revenue and assist in creating partnerships in the
health care and corporate communities. The Advisory Board is
responsible for advising management and the Sepsis Alliance Board
of Directors (BOD) on matters relating to Sepsis Alliance’s
strategic planning and execution in the areas of sepsis education,
awareness, policy, and health equity.
“John was elected to the Advisory Board by the Board of
Directors because of his passion for improving sepsis diagnostics
and his industry expertise as the CEO of T2 Biosystems,” said Karin
Molander, MD, FACEP, Chair, Sepsis Alliance Board of Directors. “We
believe both his personal and professional experiences will bring a
great deal of insight to the organization and we look forward to
working with him to continue our mission of fighting sepsis to save
lives.”
Advisory Board members serve for a term of two years and terms
may be renewed indefinitely.
“I am honored to join this important role within the Sepsis
Alliance Advisory Board, with members who are entrusting me to help
meet their goals. As someone who has personally experienced a
multidrug-resistant bacterial infection after a heart transplant,
raising awareness about sepsis and finding solutions to help reduce
fatalities and improve outcomes is an incredibly personal mission,”
said Sperzel. “T2 Biosystems and Sepsis Alliance are both
mission-driven organizations dedicated to improving outcomes from
sepsis and saving lives, and playing an active role in both of them
is a natural fit for me.”
About Sepsis Alliance Sepsis Alliance is the
first and leading sepsis organization in the U.S., working to save
lives and reduce suffering by improving sepsis awareness and care.
In 2011, Sepsis Alliance designated September as Sepsis Awareness
Month to bring healthcare professionals and community members
together in the fight against sepsis. Sepsis Alliance gives a voice
to the millions of people who have been touched by sepsis – to the
survivors, and the friends and family members of those who have
survived or who have died. Since 2003, sepsis awareness in the U.S.
has risen from 19% to 71%. Sepsis Alliance is a GuideStar Gold
Rated charity. For more information, please visit www.sepsis.org.
Connect with us on Facebook, Instagram, and Twitter at
@SepsisAlliance.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and
T2Lyme™ Panel, as well as additional products for the
detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the benefits of
T2 Biosystems’ products , as well as statements that include the
words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”,
“estimate,” “may,” “should,” “anticipate,” and similar statements
of a future or forward looking nature. These forward-looking
statements are based on management's current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, (i) any inability to (a)
realize anticipated benefits from commitments, contracts or
products; (b) successfully execute strategic priorities; (c) bring
products to market; (d) expand product usage or adoption; (e)
obtain customer testimonials; (f) accurately predict growth
assumptions; (g) realize anticipated revenues; (h) incur expected
levels of operating expenses; or (i) increase the number of
high-risk patients at customer facilities; (ii) failure of early
data to predict eventual outcomes; (iii) failure to make or
obtain anticipated FDA filings or clearances within expected time
frames or at all; or (iv) the factors discussed under Item 1A.
"Risk Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2019, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 16, 2020, and other filings
the Company makes with the SEC from time to time. These and
other important factors could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While the Company may elect to update such forward-looking
statements at some point in the future, unless required by law, it
disclaims any obligation to do so, even if subsequent events cause
its views to change. Thus, no one should assume that the Company’s
silence over time means that actual events are bearing out as
expressed or implied in such forward-looking statements.
These forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of this press release.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024